Daclizumab, CAS 152923-56-3

Product Description: Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. Daclizumab (Zenapax) can be used for multiple sclerosis research[1].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Stanley L Cohan, et al. Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis. Biomedicines. 2019 Mar 11;7(1):18.

CAS Number: 152923-56-3

Molecular Weight: N/A

Compound Purity: 95.00

Research Area: Inflammation/Immunology

Solubility: 10 mM in DMSO

Target: Interleukin Related

• SKU: MEXHY-108738-1
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-108738-1
• Green Labware: No
• Package Unit: 1 mg
• Quantity Unit: STK